{"schema_version":"secwatch.filing_event.v1","accession":"0000937556-24-000004","form_type":"8-K","ticker":"MASI","cik":"0000937556","company_name":"MASIMO CORP","filed_at":"2024-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.363517+00:00","generated_at":"2026-06-07T01:13:05.977589+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Masimo reports preliminary Q4 2023 rev $541-551M; FY2024 rev guidance $2.045-2.165B","bullets":["Preliminary Q4 2023 consolidated revenue $541M-$551M; healthcare segment $336M-$341M.","Full-year 2023 consolidated revenue $2.041B-$2.051B; healthcare $1.272B-$1.277B.","FY2024 guidance: consolidated revenue $2.045B-$2.165B; healthcare $1.345B-$1.385B.","FY2024 GAAP EPS $1.91-$2.08; non-GAAP EPS (updated) $3.44-$3.60 (prior $3.00-$3.15).","Non-healthcare revenue expected to decline in FY2024 ($700M-$780M vs ~$771M in 2023)."],"urls":{"canonical":"https://secwatch.observer/filing/0000937556-24-000004","json":"https://secwatch.observer/filing/0000937556-24-000004.json","markdown":"https://secwatch.observer/filing/0000937556-24-000004.md","text":"https://secwatch.observer/filing/0000937556-24-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/937556/000093755624000004/0000937556-24-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/937556/000093755624000004/masi-20240110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:13:05.977589+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea673e4e9512ae8338d5a6e4c63420f436619af2","claim":"MASIMO CORP reported the fourth quarter and full-year ended December 30, 2023 results: revenue Consolidated revenue of $541 million to $551 million. Guidance initiated.","evidence_excerpt":"and full-year ended December 30, 2023 and provided estimates for its full-year 2024 guidance. Preliminary Fourth Quarter 2023 Financial Results: • Consolidated revenue of $541 million to $551 million; • Healthcare revenue of $336 million to $341 million; and • Non-healthcare revenue of $205 million to $210 million. Preliminary Full-Year 2023 Financial Results:","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/937556/000093755624000004/0000937556-24-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full-year ended December 30, 2023"},{"label":"Revenue","value":"Consolidated revenue of $541 million to $551 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}